QNRX · Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

42127 Pleasant Forest Court, Ashburn, VA, 20148-7349, United States
Biotechnology
Healthcare

Market Cap

16.14M

52 Wk Range

$3.25 - $23.50

Previous Close

$3.36

Open

$3.31

Volume

11,249

Day Range

$3.18 - $3.64

Enterprise Value

-16.24M

Cash

33.18M

Avg Qtr Burn

-5.77M

Insider Ownership

3.67%

Institutional Own.

55.40%

Qtr Updated

Sep 30th 2026